Can-Fite BioPharma (CANF) Investor Presentation - Slideshow

Company Overview - Can-Fite is a clinical-stage drug development company focusing on small molecule drug products in Phase II and Phase III clinical studies[3] - The company has secured corporate partnerships and licensing deals, receiving approximately $18 million to date[3, 7] - Can-Fite's platform technology mimics the body's natural mechanisms to combat cancer and inflammation, targeting the A3 adenosine receptor (A3AR)[4] Drug Development Pipeline - Piclidenoson: - Rheumatoid Arthritis: Phase III study with 50% enrollment completed; interim analysis expected in Q4 2020; targets a market estimated at $50.5 billion by 2025[6, 10, 33] - Psoriasis: Phase III study with 50% enrollment completed; interim analysis expected in Q4 2020; addresses a market projected at $11.5 billion by the end of 2020[6, 14, 33] - COVID-19: Filed IND with the FDA for a Phase II study[6, 16] - Namodenoson: - Liver Cancer: Phase III study under preparation; targets a market estimated at $3.8 billion in 2027[6, 20, 33] - NASH: Phase II study achieved primary and secondary endpoints; aims for a market valued at $35 billion to $40 billion by 2025[6, 22, 33] - CF602: - Erectile Dysfunction: Ongoing development; targets a market estimated at $3.2 billion by 2022[6] - Cannabinoid-Based Pharmaceuticals: - Targeting autoimmune, cancer, and metabolic indications through collaboration; addresses a market projected to grow to $56.7 billion by 2026[6, 30, 31] Namodenoson NASH Phase II Study Results - All NASH cases were resolved in patients treated with 25 mg Namodenoson, compared to new NASH that developed in 5% of the placebo group (p<0.009)[28] - Patients treated with 25 mg of Namodenoson had a statistically significant reduction in hepatic fibrosis as measured by the Fibrosis-4 (FIB-4) score, as compared to placebo[25] - In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5% to 13.3% of the population, as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased from 37.5% to 35.3% of the population, with p=0.08[26]